Peptide therapeutics for Alzheimer’s, Parkinson’s, and ALS face the blood-brain barrier — the central unsolved challenge in CNS drug delivery. Three BBB-penetration strategies are in clinical testing, but no peptide has yet shown Phase III efficacy. Rare neurodegenerative diseases may be the breakthrough indication.
Peptide library technologies have evolved from phage display (10⁹ diversity) to RaPID mRNA display (10¹³ diversity, 400+ non-canonical amino acids). But library size is not quality — functional diversity and physiologically relevant selection conditions determine success more than raw numbers.
Semaglutide manufacturing consumes 6.4 tons of peptide API annually across four continents, with $16.5B in capacity expansion underway. The lipidated 31-amino acid chain and 40+ process patents create formidable barriers for biosimilar entrants — only 3-4 competitors are expected by 2032.
The peptide CDMO market reached $4.2B in 2026, with Bachem, PolyPeptide, and CordenPharma controlling 60% of capacity. GLP-1 demand has effectively sold out production-scale reactors through 2028. Developers face a critical build-vs-buy decision with a 50-100 kg/year breakeven point.
Peptide biomaterials — self-assembling hydrogels and nanofibers — are entering clinical use in hemostasis, wound healing, and tissue engineering. With programmable degradation, bioactive signaling, and batch reproducibility, they address regulatory concerns about animal-derived materials like Matrigel.
Cosmetic peptides represent a $3.2B market growing at 12% annually. Signal peptides, neurotransmitter inhibitors, and carrier peptides target distinct skin biology pathways — but the permeability barrier limits efficacy to 1-5% of applied dose. The delivery system matters as much as the peptide.
Neoantigen peptide vaccines have entered Phase II with a 67% response rate in melanoma combination therapy. While mRNA approaches grab headlines, peptide vaccines offer distinct advantages: simpler manufacturing, ambient-temperature stability, and a century of regulatory precedent.
The FDA approved 28 peptide drugs from 2020 to mid-2026, with the 2025 draft guidance establishing macrocycles as a distinct regulatory category. Manufacturing deficiencies account for 41% of peptide CRLs — the single largest source of regulatory failure.
Peptide API manufacturing costs range from $300 to $50,000+ per gram depending on length and complexity. HPLC purification accounts for 30-50% of total cost. This analysis breaks down the economics and reveals where experienced CDMOs focus their optimization efforts.
AI-designed peptides have entered clinical development with diffusion models achieving 34% experimental hit rates against undruggable targets. Machine learning is compressing peptide discovery timelines from 18 months to 6 weeks, but synthesizability and drug-likeness remain unsolved challenges.
Oral peptide delivery remains the holy grail of peptide therapeutics. With Rybelsus generating $4.2B in 2025 and $1.2B in new venture funding, technologies from SNAC to ionic liquids are progressively cracking the bioavailability barrier.
Peptide-drug conjugates combine tumor-homing peptides with cytotoxic payloads for targeted cancer therapy. With 23 clinical programs and 38% response rates in ADC-resistant patients, PDCs offer superior penetration and lower manufacturing costs than antibody-based alternatives.